Key result
New oral anticoagulants linked to fewer drug-related problems than the VKA acenocoumarol.
Why the study?
Imbalance between procoagulant and anticoagulant factors causes hemorrhagic or thrombotic conditions, prompting evaluation of drug-related problems and imbalance factors in patients receiving oral anticoagulants.
What is the prevalence of drug-related problems and factors associated with anticoagulant imbalance in patients taking oral anticoagulants?
Cross-Sectional (n=258)
No
What is the prevalence of drug-related problems and factors associated with anticoagulant imbalance in patients taking oral anticoagulants?
In a Lebanese cohort, patients taking NOACs experienced fewer drug-related problems and better coagulation control compared to those on vitamin K antagonists.
Answers are grounded in this paper and cite their sources.
NOACs associated with fewer drug-related problems than acenocoumarol; leaves open generalizability and causal effects in broader populations.
The goal of this study was to identify drug-related problems (DRPs) and the factors involved in the imbalance of new oral anticoagulants (NOACs) and vitamin K antagonists in a Lebanese adult population with cardiovascular diseases. An imbalance in the hemostatic systems between procoagulant and anticoagulant factors in circulating blood produces either hemorrhagic or thrombotic conditions. A prospective cross-sectional study was conducted during 5 months in a teaching hospital. All patients at least 18 years of age taking oral anticoagulants were included in the study. A standardized questionnaire was used, and information was obtained from the patients' profiles and electronic medical records. DRPs were identified and categorized according to the Pharmaceutical Care Network Europe classification system. A total of 258 patients were included. The overall prevalence of DRPs was 87.2%; the highest prevalence was observed in patients taking acenocoumarol (96.0%), in contrast to 76.7% and 59.0% in patients taking dabigatran and rivaroxaban, respectively. Drug interaction was the most frequent DRP (83.3%), followed by inappropriate monitoring (42.6%) and excessive dose (26.7%). Having renal disease, and taking proton-pump inhibitors or nonsteroidal anti-inflammatory drugs were among the factors affecting the international normalized ratio (INR) range (adjusted odds ratio [OR α ] = 2.513, 95% confidence interval [CI] 1.238, 5.101; OR α = 2.487, 95% CI 1.139, 5.430 and OR α = 2.114, 95% CI 1.043, 4.286, respectively), whereas smoking and renal disease significantly affected activated partial thromboplastin time (aPTT) (OR α = 8.325, 95% CI 1.577, 43.965 and OR α = 6.922, 95% CI 1.471, 32.570, respectively). Patients taking NOACs had greater aPTT control and fewer DRPs, with a wide therapeutic index enabling administration of fixed doses.
No takes yet. Share an insight, caveat, or question.
Bassam et al. (2022) conducted a cross-sectional in Cardiovascular diseases requiring oral anticoagulants (n=258). New oral anticoagulants (dabigatran, rivaroxaban) vs. Vitamin K antagonist (acenocoumarol) was evaluated on Prevalence of drug-related problems (p=<0.001). New oral anticoagulants (dabigatran and rivaroxaban) were associated with a lower prevalence of drug-related problems compared to the vitamin K antagonist acenocoumarol.
Synapse has enriched 10 related papers. Consider them for comparative context: